SAR444656 (KT-474)
Sponsors
Sanofi
Conditions
Atopic DermatitisHidradenitis Suppurativa
Phase 2
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
TerminatedNCT06028230
Start: 2023-09-29End: 2025-11-12Updated: 2025-12-11
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
TerminatedNCT06058156
Start: 2023-11-09End: 2025-11-20Updated: 2025-12-11